160 related articles for article (PubMed ID: 27566180)
1. Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma.
Tabouret E; Denicolai E; Delfino C; Graillon T; Boucard C; Nanni I; Padovani L; Figarella-Branger D; Chinot O
J Neurooncol; 2016 Dec; 130(3):431-437. PubMed ID: 27566180
[TBL] [Abstract][Full Text] [Related]
2. Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Tabouret E; Tchoghandjian A; Denicolai E; Delfino C; Metellus P; Graillon T; Boucard C; Nanni I; Padovani L; Ouafik L; Figarella-Branger D; Chinot O
Oncotarget; 2015 May; 6(13):11664-75. PubMed ID: 25860928
[TBL] [Abstract][Full Text] [Related]
3. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.
Abounader R; Ranganathan S; Lal B; Fielding K; Book A; Dietz H; Burger P; Laterra J
J Natl Cancer Inst; 1999 Sep; 91(18):1548-56. PubMed ID: 10491431
[TBL] [Abstract][Full Text] [Related]
4. [Temozolomide in patients with a glioblastoma multiforme: new developments].
Bromberg JE; Postma TJ
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689
[TBL] [Abstract][Full Text] [Related]
5. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review).
Moriyama T; Kataoka H; Koono M; Wakisaka S
Int J Mol Med; 1999 May; 3(5):531-6. PubMed ID: 10202187
[TBL] [Abstract][Full Text] [Related]
6. Epidermal Growth Factor Receptor Expression Predicts Time and Patterns of Recurrence in Patients with Glioblastoma After Radiotherapy and Temozolomide.
Tini P; Nardone V; Pastina P; Battaglia G; Miracco C; Carbone SF; Sebaste L; Rubino G; Cerase A; Pirtoli L
World Neurosurg; 2018 Jan; 109():e662-e668. PubMed ID: 29061455
[TBL] [Abstract][Full Text] [Related]
7. Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide.
Tieu MT; Lovblom LE; McNamara MG; Mason W; Laperriere N; Millar BA; Ménard C; Kiehl TR; Perkins BA; Chung C
J Neurooncol; 2015 Aug; 124(1):119-26. PubMed ID: 26015297
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
[TBL] [Abstract][Full Text] [Related]
9. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
10. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma.
Kocher M; Frommolt P; Borberg SK; Rühl U; Steingräber M; Niewald M; Staar S; Stuschke M; Becker G; Fischedick AR; Herfarth K; Grauthoff H; Müller RP
Strahlenther Onkol; 2008 Nov; 184(11):572-9. PubMed ID: 19016015
[TBL] [Abstract][Full Text] [Related]
11. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
[TBL] [Abstract][Full Text] [Related]
12. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma.
Gerstein J; Franz K; Steinbach JP; Seifert V; Fraunholz I; Weiss C; Rödel C
Radiother Oncol; 2010 Dec; 97(3):382-6. PubMed ID: 20850883
[TBL] [Abstract][Full Text] [Related]
13. c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme.
Liu W; Fu Y; Xu S; Ding F; Zhao G; Zhang K; Du C; Pang B; Pang Q
J Clin Neurosci; 2011 Jan; 18(1):119-21. PubMed ID: 20832323
[TBL] [Abstract][Full Text] [Related]
14. Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.
Garnett J; Chumbalkar V; Vaillant B; Gururaj AE; Hill KS; Latha K; Yao J; Priebe W; Colman H; Elferink LA; Bogler O
Neoplasia; 2013 Jan; 15(1):73-84. PubMed ID: 23359207
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
16. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation.
Lal B; Xia S; Abounader R; Laterra J
Clin Cancer Res; 2005 Jun; 11(12):4479-86. PubMed ID: 15958633
[TBL] [Abstract][Full Text] [Related]
17. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
Badiyan SN; Markovina S; Simpson JR; Robinson CG; DeWees T; Tran DD; Linette G; Jalalizadeh R; Dacey R; Rich KM; Chicoine MR; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):877-85. PubMed ID: 25257812
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
[TBL] [Abstract][Full Text] [Related]
19. Met and its ligand HGF are associated with clinical outcome in breast cancer.
Veenstra C; Pérez-Tenorio G; Stelling A; Karlsson E; Mirwani SM; Nordensköljd B; Fornander T; Stål O
Oncotarget; 2016 Jun; 7(24):37145-37159. PubMed ID: 27175600
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide.
Pinel B; Duchesne M; Godet J; Milin S; Berger A; Wager M; Karayan-Tapon L
J Neurooncol; 2017 Apr; 132(2):287-294. PubMed ID: 28070830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
